Tevogen Bio Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$9.50next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Balance Quarterly692.3KTarget: Sufficient capital to fund operations for at least 12 months
Quarterly Net Loss Quarterly-5.5MTarget: Narrowing losses through cost-disciplined operations
Product Revenue Quarterly0.0Target: Long-term commercialization of T-cell therapies
Watch Items
- Nasdaq Continued Listing ComplianceTrigger: Market value of listed and publicly held shares below thresholdAction: Regain compliance by mid-October 2026 deadline
- Clinical Trial Initiation for TVGN 489Trigger: Securing additional external funding to launch next clinical phaseAction: Finalize clinical manufacturing infrastructure and launch trials in Long COVID and immunocompromised patients
- Strategic Acquisitions and Revenue DiversificationTrigger: Closing of evaluated transactions (CRO, MSO, Healthcare Services)Action: Complete due diligence and execute definitive agreements to target over $50 million to $100 million in combined annual revenue
Research as of 19 Jun 2026